697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 9092 0480
https://www.neurenpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 1.07M | N/A | N/A |
Ms. Lauren Frazer C.A. | CFO & Company Secretary | N/A | N/A | N/A |
Mr. Lawrence Glass BA (Biology) | Chief Science Officer | N/A | N/A | N/A |
Mr. Gerry Zhao | Vice President of Corporate Development | N/A | N/A | N/A |
Dr. Liza A. Squires M.D. | Chief Medical Officer | N/A | N/A | N/A |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Neuren Pharmaceuticals Limited’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 1; Compensation: 5.